ライフサイエンスコーパス: longterm

1 s fairly resistant to TALL-104 cell lysis in longterm 51Cr-release assays but can be totally growth i

2 ree of sustained marrow engraftment to allow longterm amelioration of the inherited disease phenotype

3 Longterm benefits, harms and the cost-effectiveness of t

4 critical care, mental health acute care, and longterm care nursing units (called Community Living Cen

5 ide levels, perhaps occurring in response to longterm changes in illumination or other environmental

6 mphatic filariasis (LF) are limited in their longterm clearance of microfilaria from the blood.

7 Longterm complications, however, including infections, b

8 how effective catheter ablation will be as a longterm cure for this type of VT.

9 Understanding longterm deep tissue damage caused by UV radiation is im

10 s for the treatment of cancer with promising longterm, durable monotherapy activity in double-hit dif

11 tment (mediastinal irradiation) results in a longterm dysregulation of T-cell subset homeostasis.

12 synaptic plasticity mechanisms that mediate longterm effects of the drug.

13 disoproxil fumarate (TDF) in an open-label, longterm extension of two phase 3 studies.

14 tumors of various pathogenetic subsets with longterm follow-up.

15 re after a tarsometatarsal amputation with a longterm follow-up.

16 Interest in nonimmunologic factors affecting longterm graft survival has focused on adequacy of nephr

17 ses against islet cells and markedly enhance longterm graft survival.

18 ing the cells' potential for engraftment and longterm hematopoiesis.

19 m can provide an effective means of inducing longterm immunological tolerance and has been documented

20 Additional longterm immunosuppressive therapy was necessary in 36%

21 ptimized to support the acute, lytic and the longterm, latent phase of infection.

22 approaches are broadly applicable or affect longterm medication adherence and health outcomes.

23 tants show normal early memory but defective longterm memory.

24 red with appropriate supervision, can reduce longterm neurologic disability in premature infants.

25 ifts in hearing may occur over the course of longterm or open-ended therapy; consequently, age-adjust

26 ollowing OLT for chronic hepatitis C and the longterm outcome following retransplantation in a large

27 nnovative topical agents that achieve better longterm outcomes with fewer side effects.

28 We describe, for the first time, longterm patency of fully histoincompatible orthotopic t

29 and nondiabetic patients exhibit comparable longterm patency.

30 s synaptic transmission and the magnitude of longterm potentiation (LTP) in adult rodent hippocampal

31 er but not other disorders, increased use of longterm psychiatric and medical services, and overall i

32 hip between age at onset and both gender and longterm responsivity to neuroleptic drugs.

33 hould be further evaluated prospectively for longterm safety.

34 ns in the treatment of CNS leukemia, and the longterm sequelae of CNS-directed therapy, focusing on a

35 tant BALB/c mice, then followed to determine longterm survival and whether or not they developed sign

36 However, longterm survival is difficult to achieve on FK506 recip

37 Grafts from longterm survivors ( > 120 d) treated with CTLA4Ig showe

38 cancers were diploid and both patients were longterm survivors (over 5 years).

39 II kinase-alpha) plays an important role in longterm synaptic plasticity.

40 me mobile-telephone users and people exposed longterm to base-station radiation.

41 FMT delivery system and may be preferred for longterm treatment strategies in UC and other chronic di

42 several disadvantages and are unreliable for longterm use.

43 nts that price these resources at their true longterm value.

44 rt the effects of the passage of time on the longterm visual knowledge for objects in a patient with